Haitian Innovation Company(HYTNF), first sold medical cannabis in Germany and received reorders... The anticipated easing of regulations in the United States is spreading.

Canadian pharmaceutical-grade cannabis manufacturer HighTide Innovations Inc. (HYTNF) has achieved initial sales and repeat orders in the German medical cannabis market, accelerating its global expansion strategy. With commercial validation in a strictly regulated market coupled with the loosening of cannabis regulations in the U.S., market expectations for its growth continue to rise.

HighTide Innovations Inc. (HYTNF) announced on March 27, 2026 (local time) that its wholesale cannabis products exported to Germany have completed all local sales processes and are officially on the market. After completing Germany’s stringent regulatory procedures, including import permits, quality inspections, and market approval, the product has begun circulation. The company also stated that it has received additional repeat orders, emphasizing that this demonstrates the substantive competitiveness of its production system based on “GMP (Good Manufacturing Practices and Quality Management Standards).”

Germany is considered to have the strictest regulations in the European medical cannabis market. HighTide has previously completed supply chain validation and met quality standards for supplying approximately 4,000 kilograms of cannabis raw materials to this market. Industry experts believe that this sales launch and repeat orders are not just one-time exports but may develop into long-term supply agreements. A European pharmaceutical distribution expert commented, “Receiving repeat orders in the German market means that both its quality and compliance capabilities have been recognized, which is a positive signal for future expansion into similarly regulated markets like the UK and Australia.”

The company recently appointed Fabian Monaco, who has experience in venture capital and private equity investment, to its board, enhancing its capital market response capabilities. Monaco previously grew cannabis company Gage Growth to a sales scale of $100 million (approximately 144 billion KRW) and ultimately facilitated a sale valued at over $500 million (approximately 720 billion KRW). This is expected to play an important role in its future global business expansion and fundraising strategy.

Changes in U.S. policy have also become a variable affecting the company’s medium to long-term growth prospects. President Trump issued an executive order in December 2025 directing the initiation of procedures to reclassify cannabis from the current “Schedule I” to “Schedule III.” If this measure is implemented, cannabis will be managed as a drug at the federal level, restructuring its manufacturing and distribution systems under FDA and DEA oversight.

HighTide has obtained drug manufacturing licenses (DEL), cannabis drug licenses (CDL) issued by the Canadian health department, and GMP certification applicable to the U.S. The company also has experience exporting to the UK, Germany, and Australia, which is believed to have laid the foundation for a rapid response in the increasingly regulated U.S. market.

Particularly, the company’s core competitiveness lies in its production capacity of “pharmaceutical-grade cannabis.” This means its target is not merely the consumer goods market but rather entry into the prescription drug market. In fact, the CBD-based drug “Epidiolex” recorded sales of $972.4 million (approximately 1.4 trillion KRW) and over 88% high profit margins in 2024, proving the potential of this market.

At the same time, HighTide is diversifying its product portfolio by developing GMP standard e-cigarette products in collaboration with SNDL and expanding beverage production with A1 Cannabis. The company is also building a pharmaceutical-grade quality management system by strengthening stability testing programs and global supply chain certification procedures.

“Comments” indicate that the global cannabis market is rapidly restructuring around two main axes: regulatory relaxation and drug conversion. With its achievements in the German market and GMP-based manufacturing competitiveness, HighTide Innovations Inc. is rising as an early beneficiary of this transformation. If future changes in U.S. policy become a reality, the company’s growth trajectory is likely to become even steeper.